Content about Levetiracetam

March 13, 2014

The epilepsy therapeutics market value in the eight major countries — the United States, Canada, France, Germany, Italy, Spain, the United Kingdom and Japan — will increase from $3.4 billion in 2012 to $4.5 billion by 2019, at a compound annual growth rate of 3.9%, according to a new report from business intelligence provider GBI Research.

NEW YORK — The epilepsy therapeutics market value in the eight major countries — the United States, Canada, France, Germany, Italy, Spain, the United Kingdom and Japan — will increase from $3.4 billion in 2012 to $4.5 billion by 2019, at a compound annual growth rate of 3.9%, according to a new report from business intelligence provider GBI Research.

July 26, 2012

Qualitest Pharmaceuticals announced that it has received approval from the Food and Drug Administration for its generic version of an epilepsy treatment.

HUNTSVILLE, Ala. — Qualitest Pharmaceuticals announced that it has received approval from the Food and Drug Administration for its generic version of an epilepsy treatment.

The drug maker said its abbreviated new drug application for levetiracetam extended-release tablets, in the 500-mg and 750-mg strength, was approved. The drug is a generic version of UCB's Keppra XR.

Total combined sales for levetiracetam extended-release tablets were approximately $124.8 million for the 12 months ended in May, according to IMS Health data.

February 29, 2012

The Food and Drug Administration has approved a drug for epilepsy made by Hi-Tech Pharmacal, the drug maker said Wednesday.

AMITYVILLE, N.Y. — The Food and Drug Administration has approved a drug for epilepsy made by Hi-Tech Pharmacal, the drug maker said Wednesday.

Hi-Tech announced the approval of levetiracetam oral solution in the 100 mg-per-milliliter strength. The drug is a generic version of UCB Pharma's Keppra oral solution and is used to treat partial onset seizures in people ages 16 years and older.

Various versions of the drug had sales of $62 million in 2011, according to IMS Health. Hi-Tech said it plans to launch the drug in May.

January 3, 2012

The Food and Drug Administration has approved a drug for epilepsy made by Mylan, the drug maker said.

PITTSBURGH — The Food and Drug Administration has approved a drug for epilepsy made by Mylan, the drug maker said.

The FDA approved Mylan's levetiracetam extended-release tablets in the 500-mg and 750-mg strengths.

The drug is a generic version of UCB's Keppra XR, used to treat partial onset seizures in epilepsy patients ages 16 years and older.

Various versions of the drug had sales of about $162.8 million during the 12-month period ended in September, according to IMS Health.

October 4, 2011

A wave of patent expirations over the next several years will open up a broad swath of drugs to generic competition, and India's Lupin Pharmaceuticals is looking to benefit, according to published reports.

NEW YORK — A wave of patent expirations over the next several years will open up a broad swath of drugs to generic competition, and India's Lupin Pharmaceuticals is looking to benefit, according to published reports.

The Wall Street Journal reported that the Mumbai-based company planned to launch 25 to 30 new generic drugs each year over the next couple of years.

September 16, 2011

Actavis has launched its version of an epilepsy drug made by UCB.

MORRISTOWN, N.J. — Actavis has launched its version of an epilepsy drug made by UCB.

The generic drug maker said it received approval from the Food and Drug Administration for levetiracetam extended-release tablets and commenced shipping the product following approval. The drug is the generic equivalent of Keppra XR.

U.S. sales of Keppra XR were about $161 million for the 12 months ended June 30, according IMS Health data.

September 15, 2011

The Food and Drug Administration has approved a generic drug for epilepsy made by Lupin Pharmaceuticals, the drug maker said.

BALTIMORE — The Food and Drug Administration has approved a generic drug for epilepsy made by Lupin Pharmaceuticals, the drug maker said.

Lupin announced the approval and launch of levetiracetam extended-release tablets in the 500-mg and 750-mg strengths.

The drug is a generic version of UCB's Keppra XR, which had sales of about $161 million during the 12-month period ended in June, according to IMS Health.

September 13, 2011

Watson Labs has begun shipping a drug designed to treat partial onset seizures in patients with epilepsy.

MORRISTOWN, N.J. — Watson Labs has begun shipping a drug designed to treat partial onset seizures in patients with epilepsy.

The drug maker said it launched levetiracetam extended-release tablets in the 500-mg and 750-mg strengths. The drug is a generic version of UCB's Keppra XR. The drug is indicated to treat patients ages 16 years and older.

Watson said it began shipping the drug on Tuesday following approval of its abbreviated new drug application from the Food and Drug Administration.

August 10, 2011

The Food and Drug Administration has approved a generic drug for epilepsy.

PISCATAWAY, N.J. — The Food and Drug Administration has approved a generic drug for epilepsy.

Innopharma announced the FDA approval of levetiracetam injection. The drug is a generic version of UCB's Keppra.

Innopharma has a licensing agreement with X-GEN Pharmaceuticals for marketing and distribution of the drug.

July 11, 2011

Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.

BRIDGEWATER, N.J. — Generic drug maker Amneal has launched three new liquid drugs, the company said Monday.

February 1, 2010

The Food and Drug Administration has approved a generic epilepsy drug made by Taro Pharmaceutical...